Haddox V G, Bidder T G, Waldron L E, Derby P, Achen S M
West J Med. 1987 Jun;146(6):695-6.
Clorazepate dipotassium was administered orally for the five-day prophylactic treatment of potential, incipient and overt withdrawal signs and symptoms in 226 patients on admission to an inpatient alcohol treatment unit. Conservative estimates based on these patients' histories and on literature reports predicted that between 7 and 40 (3% to 18%) of these persons would be expected to have a withdrawal convulsion. No patients experienced convulsions. This complete absence of seizures suggests that clorazepate is effective in counteracting convulsive and other manifestations of the alcohol withdrawal syndrome.
对226名入住住院酒精治疗单元的患者口服双钾氯氮卓，进行为期五天的预防性治疗，以应对潜在、初期和明显的戒断体征及症状。根据这些患者的病史及文献报告进行的保守估计预测，这些患者中有7至40人（3%至18%）可能会发生戒断性惊厥。但没有患者出现惊厥。完全没有发作表明氯氮卓在对抗酒精戒断综合征的惊厥及其他表现方面是有效的。
